Epoetin alfa
| Clinical data | |
|---|---|
| Pronunciation | /ɛˈpoʊ.ɪtɪn/ |
| Trade names | Epogen |
| Biosimilars | epoetin alfa-epbx, Abseamed, Binocrit, Epoetin Alfa Hexal, Retacrit |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692034 |
| License data |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C815H1317N233O241S5 |
| Molar mass | 18396.19 g·mol−1 |
| (what is this?) (verify) | |
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. Epoetin alfa is an erythropoiesis-stimulating agent. It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen.
It is on the World Health Organization's List of Essential Medicines. It was approved for medical use in the European Union in August 2007,